OncoMatch/Clinical Trials/NCT03678025
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Is NCT03678025 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for castration levels of testosterone.
Treatment: Abiraterone · Bicalutamide · Degarelix · Docetaxel · Flutamide · Goserelin Acetate · Histrelin Acetate · Leuprolide Acetate · Nilutamide · Prednisone · Triptorelin — This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage IV, IVA, IVB
Metastatic disease required
Performance status
ZUBROD 0–1
Demographics
Prior therapy
Must have received: standard systemic therapy — metastatic
Patients must have received between 22 and 28 weeks of SST as measured from the date of first hormonal therapy or surgical castration. SST is defined by current NCCN guidelines for metastatic prostate cancer.
Cannot have received: local therapy for prostate adenocarcinoma (brachytherapy, high-intensity focused ultrasound, cryotherapy, laser ablative therapies)
Exception: prior therapy for benign conditions allowed
No prior local therapy for prostate adenocarcinoma is allowed (e.g., brachytherapy, high-intensity focused ultrasound [HIFU], cryotherapy, laser ablative therapies). Any prior therapy for benign conditions, such as obstruction, are acceptable (e.g., transurethral resection of the prostate, greenlight laser ablation, microwave ablation).
Cannot have received: docetaxel (docetaxel)
Exception: not allowed after randomization
Patients must not be planning to receive docetaxel after randomization.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Cancer Center at Saint Joseph's · Phoenix, Arizona
- Mayo Clinic Hospital in Arizona · Phoenix, Arizona
- Mayo Clinic in Arizona · Scottsdale, Arizona
- University of Arizona Cancer Center-Orange Grove Campus · Tucson, Arizona
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03678025 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior local therapy for prostate adenocarcinoma, docetaxel disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV or IVA or IVB is required (metastatic disease required).
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages